AI Radiology Vendor Shortlist: How to Narrow From 10 to 3 in 2 Weeks

The Real Problem With Vendor Comparison Matrices

When I talk to hospital IT directors who've just completed an AI radiology vendor selection, their most common regret isn't about the vendor they chose—it's about the process that got them there. Most teams inherited a spreadsheet with 12 features and 8 vendors, scored each cell on a 1-5 scale, and declared the vendor with the highest total "the winner." Spreadsheets like this are usually garbage.

Why? Feature matrices ignore two things that determine whether an AI radiology deployment succeeds: clinical validation robustness and deployment complexity. A vendor that claims 96% accuracy on chest x-rays might have validated that claim on 500 images from a single hospital system. Another might cite the same 96% figure based on prospective validation across 47 hospitals, 180,000 exams, and published peer review. These are categorically different claims. A feature matrix treats them as equivalent.

The same logic applies to deployment. Two vendors might both promise pacs integration, but one means "we connect to your HL7 feed and you run the AI in Docker on an on-premises GPU server," while the other means "we ingest your dicoms into our cloud, run analysis, and push results back via your PACS API, handling RBAC and audit logs." The second involves months of IT work; the first might take weeks. Most procurement teams don't discover this difference until contract negotiation.

This article outlines a 2-week vendor evaluation process that separates procurement theater from clinical reality and deployment feasibility. It's built on conversations I've had with radiologists, IT directors, and procurement officers at 15+ hospitals deploying AI radiology systems. The goal: shortlist three vendors in 14 days with confidence that each one will actually work in your environment and deliver the clinical value you're paying for.

Step 1: Clinical Validation Credibility Check (Days 1-2)

Before you even schedule a vendor demo, run their accuracy claims through a credibility filter. Not all 97.9% detection rates are equal.

When we were validating the brain mri tumor detection engine at Fractify, we ran a prospective study across three hospital networks. The accuracy held: 97.9% sensitivity for brain tumors over 8mm at detection stage. But "prospective" and "multi-center" are the only words that matter in that sentence. A vendor can claim 99% accuracy on a 200-image retrospective dataset from their home hospital and technically be correct. That number is essentially worthless for your procurement decision.

Create a simple clinical validation rubric—ask each vendor these three questions in writing:

1. Is the accuracy claim from a prospective or retrospective study? Retrospective studies overestimate real-world accuracy by 10-20 percentage points because the images are pre-selected and radiologists optimize for known pathologies. Prospective studies are the only credible baseline.

2. How many hospital systems contributed data? Single-hospital validation tells you the vendor can work in that hospital's PACS environment, workflows, and patient population. Multi-center (3+ hospitals) tells you it works across equipment manufacturers, image preprocessing variations, and different radiologist practice patterns. This is the difference between "works somewhere" and "likely works somewhere new."

3. Is the study published or peer-reviewed? Published studies in journals like Radiology, European Radiology, or Radiology: Artificial Intelligence have undergone technical and statistical review. The claim has been vetted. Unpublished internal studies haven't. Many vendors have both; when they do, cite the published version and ask why any claims differ from what appears in peer review.

Fractify publishes validation data because it's our standard, not our exception. The 97.7% bone fracture detection rate and 18-pathology chest X-ray detection accuracy we cite are both multi-center prospective studies, published and peer-reviewed. That's the baseline you should expect from any serious radiology ai vendor.

Most vendors will claim they can't share detailed validation data due to "IP protection." That's a yellow flag. If they've already published in a peer-reviewed journal, the data is public. If they haven't published, ask: why not? Legitimate vendors publish because peer review increases trust. Vendors that resist transparency are usually hiding accuracy that doesn't hold up under external scrutiny.

For each vendor that passes the clinical validation check, advance to Step 2.

Step 2: Integration Feasibility Reality Check (Days 3-4)

Ask a doctor to describe their EHR integration expectations and they'll say "it connects to the hospital system." Ask an IT director to describe it and you get a 45-minute technical architecture conversation involving DICOM routing, HL7 message parsing, database schema alignment, and security group configuration. Most vendor shortlist failures happen here—not because the AI is bad, but because IT didn't expect the integration work.

Request from each vendor a one-page technical integration document that covers:

Architecture: Does the AI engine run on your servers (on-premises), the vendor's cloud, or hybrid? Each has IT cost implications. On-premises requires your IT to manage GPU hardware, driver updates, and security patching. Cloud requires your IT to manage DICOM encryption in-transit, HIPAA-compliant data handling, and API authentication. Hybrid requires expertise in both. Understand which one your IT team has capacity for.

Time-to-deployment: Ask: "If we signed a contract today and had a test PACS environment ready, what's the minimum time to production deployment?" Most vendors will say 8-12 weeks. Dig into why. Is it due diligence (network security review, IRB approval if running studies), technical integration work, or training? Hospitals that surprise themselves during procurement have dramatically underestimated training time.

Prior-study comparison: Can the AI engine access prior imaging via your PACS, and does it use that context for detection? This is non-negotiable for conditions like acute stroke (prior imaging defines what's "new") and for reducing false positives in chronic conditions (comparing to baseline). Ask whether the vendor's algorithm actually integrates prior-study comparison or just outputs a confidence score. These are different. The former is a feature; the latter is a baseline that every serious AI vendor should have.

Honestly, this is where many vendors stumble. They've optimized their algorithm for stand-alone images because that's simpler to deploy at scale. When hospitals ask "will it use prior studies," the answer is often "our roadmap includes that" rather than "yes, today." If prior-study comparison matters to your deployment (it should for most use cases), don't let a vendor tell you it's a future feature. It should be present capability.

One practical check: ask the vendor which DICOM standards they support. DICOM compliance at the image-level (tags, color space, compression) is one thing. DICOM compliance at the infrastructure-level (query/retrieve operations, grad-cam heatmap overlay in standard DICOM format, integration with RBAC systems) is harder. Vendors that cite the full DICOM standard at dicomstandard.org have done the engineering work. Vendors that say "we support DICOM" without specifics probably haven't.

For integration to be real, request a technical proof-of-concept: the vendor sends a representative to your hospital for a half-day session, connects to your test PACS environment, and ingests 50 historical images. If they can do this cleanly in one session, they've done PACS integrations before. If they need multiple visits or hit blockers (network topology issues, PACS query limits, firewall config), integration will take longer than they quoted.

Step 3: The Accuracy-in-Your-Environment Question (Days 5-6)

Clinical validation data from the vendor is not the same as performance in your specific environment. Your hospital might have older PACS systems, different scanner manufacturers, or patient populations with disease prevalence that differs from the vendor's validation cohort.

Here's the question that separates vendors who can deploy with confidence from vendors who are guessing: "If we deploy your system, what's your plan to measure actual performance in our environment during the first month? What metrics will you track, and how will you handle cases where our performance differs from your published accuracy?"

Fractify builds this into our deployment protocol. We establish a 30-day monitoring phase where the system runs in parallel with radiologist reads (not in the clinical workflow yet). We track sensitivity, specificity, and Grad-CAM heatmap agreement with radiologist markup for a subset of cases. This tells us whether the published accuracy holds in the new environment. If performance drifts—say, down to 94% sensitivity instead of the published 97.9%—we work with your radiology team to understand why (different scanner model, different patient population, different image preprocessing). This is normal and expected. What's not acceptable is to deploy and then assume published accuracy is reflected in your environment without measuring it.

Vendors that have a rigorous monitoring plan are betting on their accuracy claims being real. Vendors that dismiss this monitoring as "unnecessary overhead" are taking a gamble that the published numbers hold.

Step 4: Cost Reality (Days 7-10)

Most hospitals learn too late that AI vendor pricing is structured to hide integration and training costs. A vendor might quote "$0.50 per study" and a hospital thinks "okay, 100,000 studies per year is $50,000." The actual cost is $50,000 in licensing plus $80,000 in integration consulting, $40,000 in IT infrastructure, and $20,000 in radiologist and technician training. Real cost-of-ownership is $190,000 year one, not $50,000.

Create a spreadsheet for each vendor and ask them to itemize Year 1 and Year 3 costs across all six categories. This forces honesty. A vendor that bundles everything as "per-study pricing" hasn't thought through the full deployment or is deliberately obscuring cost.

Pay close attention to the integration cost. I've seen hospitals choose a lower-cost AI engine and then spend 3x that amount in integration consulting because the vendor oversimplified the architecture. Conversely, I've seen hospitals spend heavily on integration and then have IT manage it cleanly because the vendor was clear about what was required upfront.

Step 5: Vendor Stability & Contract Terms (Days 11-14)

The final filter: is this vendor stable enough that they'll still be in business in 3-5 years? Radiology AI is a competitive market with consolidation pressure. You don't want to sign a 5-year contract with a vendor and then have them acquired and sunset 18 months later.

Request from each vendor:

Financial information: How many years has the company been operating? What's their funding status? If they're venture-backed, when was their last funding round and how much runway do they have? A company that raised $50M in 2023 with a burn rate of $8M/month is fine. A company that raised $10M and is burning $3M/month is a risk.

Customer reference list: How many hospitals are running their system in production? Call 3-5 and ask: "How long have you been live? Any major issues? Would you choose this vendor again?" Most will say yes; some will be honest about integration challenges or accuracy gaps in specific use cases.

Contract terms: Request a summary of key terms: the service level agreement (uptime %), penalties for underperformance (if the AI sensitivity drops below X%, what happens?), data ownership and exit procedures (if you leave, how do you retrieve your data?), and update frequency (how often does the model improve?). Fractify publishes its standard terms because we stand by them. Vendors that push back on showing contract terms before negotiation are hiding something.

Expert Insight: The Integration Timeline Reality

How to Frame Your Shortlist Decision

After 2 weeks, you'll have clinical validation data, integration feasibility assessments, cost-of-ownership numbers, and vendor stability insights for each of the original 10. Most hospitals find that 3-4 vendors pass all five steps rigorously. These are your shortlist.

The three finalists you advance to contract negotiation should meet these criteria:

Clinical criteria: All accuracy claims are prospective, multi-center, and peer-reviewed (or have published peer-reviewed studies from the vendor). Predicted accuracy in your environment is realistic based on your scanner mix and patient population.

Integration criteria: The vendor has deployed to hospitals with similar PACS systems and IT capacity to yours. Timeline-to-production is 16-20 weeks, not 8 weeks. They've agreed to a 30-day parallel-run monitoring phase to measure actual performance.

Cost criteria: Total cost-of-ownership (Year 1) is clear and defensible. There are no hidden integration or training costs. Per-study cost scales appropriately with volume.

Stability criteria: The vendor has been operating for 3+ years, has sufficient funding runway, has 5+ hospitals live on their system, and publishes contract terms upfront.

Once you have three candidates meeting all criteria, negotiate from a position of strength. You know their true capabilities, you've verified they can integrate into your environment, and you understand the realistic cost and timeline. The difference between this and starting contract negotiation with the original vendor list is dramatic: less surprise, lower risk, faster deployment, and higher confidence in the vendor choice.

When to Deviate From This Framework

This 2-week evaluation framework works for hospitals deploying AI radiology as a core clinical tool. I haven't seen enough data to say definitively whether a shorter timeline (5-7 days) works if you're evaluating only 3-4 vendors, or whether it scales to 15+ vendors without becoming administratively overwhelming. For most mid-size hospitals (100-300 beds) evaluating 8-12 vendors, 2 weeks is realistic.

One scenario where I'd modify the framework: if you have a preferred vendor already (perhaps they've done a proof-of-concept in your radiology department), you can compress Steps 1-3 by leveraging the PoC data. You've essentially already validated clinical accuracy and integration feasibility. Move straight to cost negotiation and vendor stability checks. This cuts the timeline to 5-7 days but only works if the PoC was genuine (prospective validation, not just demos).

A Note on Fractify's Approach

Fractify—built by Databoost Sdn Bhd (Malaysia) and designed specifically for hospital radiology workflows—is built to pass all five evaluation steps cleanly. Our brain MRI tumor detection engine (97.9% sensitivity across 3 hospital networks, peer-reviewed), bone fracture detection (97.7% sensitivity, prospective multi-center), and 18-pathology chest X-ray engine (published in peer review) all meet the clinical validation criteria. Our PACS integration works on both on-premises and hybrid architectures, integrates prior-study comparison by default, and our implementation timeline for hospitals with existing PACS infrastructure is typically 12-16 weeks. Our pricing is transparent—no hidden integration costs—and we include 30-day monitoring as standard protocol. We've been operating since 2018 and deploy to hospitals across Southeast Asia and beyond.

That said, Fractify won't be the right choice for every hospital. If your institution has legacy PACS infrastructure that predates HL7 integration, vendors with longer histories of legacy-system adaptation might be better suited. If you need specific pathology detection that falls outside chest X-ray, brain MRI, and bone imaging (say, mammography or ultrasound-guided biopsy assistance), you'll find vendors more specialized in those modalities. The framework above forces you to ask these questions and choose based on your needs, not vendor marketing.

The Actual Outcome

Hospitals that follow this framework report two consistent outcomes: (1) the shortlist of three vendors is dramatically more confident—decision-makers know why they're advancing each one, (2) contract negotiation is faster because both parties understand the scope clearly. The process isn't about finding a perfect vendor; it's about narrowing from 10 to 3 with realistic expectations about clinical performance, integration complexity, cost, and risk. From there, any of the three will likely succeed.

FAQ